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a b s t r a c t
Despite major advances in high-throughput and computational modelling techniques, understanding of
the mechanisms regulating tissue speciﬁcation and differentiation in higher eukaryotes, particularly
man, remains limited. Microarray technology has been explored exhaustively in recent years and several
standard approaches have been established to analyse the resultant datasets on a genome-wide scale.
Gene expression time series offer a valuable opportunity to deﬁne temporal hierarchies and gain insight
into the regulatory relationships of biological processes. However, unless datasets are exactly synchro-
nous, time points cannot be compared directly.
Here we present a data-driven analysis of regulatory elements from a microarray time series that
tracked the differentiation of non-immortalised normal human urothelial (NHU) cells grown in culture.
The datasets were obtained by harvesting differentiating and control cultures from ﬁnite bladder- and
ureter-derived NHU cell lines at different time points using two previously validated, independent
differentiation-inducing protocols. Due to the asynchronous nature of the data, a novel ranking analysis
approach was adopted whereby we compared changes in the amplitude of experiment and control time
series to identify common regulatory elements. Our approach offers a simple, fast and effective ranking
method for genes that can be applied to other time series.
The analysis identiﬁed ELF3 as a candidate transcriptional regulator involved in human urothelial
cytodifferentiation. Differentiation-associated expression of ELF3 was conﬁrmed in cell culture experi-
ments and by immunohistochemical demonstration in situ. The importance of ELF3 in urothelial
differentiation was veriﬁed by knockdown in NHU cells, which led to reduced expression of FOXA1
and GRHL3 transcription factors in response to PPARγ activation. The consequences of this were seen in
the repressed expression of late/terminal differentiation-associated uroplakin 3a gene expression and in
the compromised development and regeneration of urothelial barrier function.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The bladder and associated lower urinary tract is lined by
urothelium, a transitional epithelium that functions as a perme-
ability barrier to limit exposure to urinary toxins and to minimise
alterations in urine and blood composition ((Fellows and Marshall,
1972); reviewed (Lewis, 2000)). The maintenance of this vital
urinary barrier is supported by an exceptional regenerative capa-
city, whereby the urothelium switches from a mitotically-
quiescent to a highly proliferative state in response to damage
(Lavelle et al., 2002).
Urothelium shows an increase in morphological complexity
between basal, intermediate and superﬁcial cell zones. The lumen-
facing superﬁcial cells are uniquely specialised to provide urinary
barrier function. With well-developed tight junctions limiting
paracellular permeability (Varley et al., 2006), the major transur-
othelial barrier is provided by thickened plaques of asymmetric
unit membrane (AUM) decorating the apical membrane of the
superﬁcial cells (Hicks, 1965). The AUM is constituted in the Golgi
as a result of precise uroplakin protein interactions (reviewed (Wu
et al., 2009)), the disruption of which has devastating conse-
quences for urothelial permeability and urinary tract develop-
ment. Thus, the targeted disruption of the uroplakin UPK3a gene
in mice resulted in distinctive structural and functional
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abnormalities of the urothelium and high grade vesicoureteric
reﬂux (Hu et al., 2002). Although a few examples of minor
uroplakin gene anomalies associated with urinary tract malforma-
tions have since been found in man (Jenkins et al., 2005), there is
no common association (Garthwaite et al., 2006; Giltay et al.,
2004; Jiang et al., 2004; Kelly et al., 2005), indicating that major
disruption of urothelial differentiation during human develop-
ment is likely non-viable.
Although morphological and molecular features of urothelial
differentiation are well characterised, relatively little is known of
the transcriptional mechanisms underpinning this process. In
mice, Kruppel-like factor 5 (KLF5) has been shown to be involved
in the embryological development and differentiation of bladder
urothelium (Bell et al., 2011). In the same study, KLF5-null foetal
urothelium was shown to be deﬁcient for expression of PPARγ,
GRHL3, ELF3 and OVOL1, supporting the participation of these
factors in a hierarchical transcriptional network regulating urothe-
lial development. The authors further showed in transient trans-
fection assays that KLF5 regulated expression of the mGRHL3
promoter. In mouse development, GRHL3 plays an essential role in
epidermal morphogenesis, with GRHL3-deﬁcient mice exhibiting
failed skin barrier formation, defective wound repair and loss of
eyelid fusion (Boglev et al., 2011). GRLH3 has also been shown to
be critical to urothelial differentiation during mouse development
(Yu et al., 2009). Although it is assumed that these factors and
relationships are conserved from mouse to man, there is a lack of
experimental approach to enable these developmental relation-
ships to be assessed in human cells.
We have developed a robust experimental system for the propaga-
tion and differentiation of normal human urothelial (NHU) cells
in vitro. When isolated from the tissue and cultured in a serum-free
low calcium medium as ﬁnite cell lines, NHU cells subsume a basal
squamous (CK14þ) phenotype, are highly proliferative and do not
show spontaneous differentiation even at conﬂuence (Southgate et al.,
1994). Nevertheless, cultured NHU cells retain the capacity to differ-
entiate to form a functional barrier urothelium, as shown by sub-
culture in medium containing bovine serum and physiological [Ca2þ],
where transepithelial electrical resistances of 43000 Ω cm2 are
routinely attained (Cross et al., 2005). In addition, pharmacological
activation of the nuclear receptor peroxisome proliferator activated
receptor gamma (PPARγ) initiates the urothelial differentiation gene
expression programme in individual cells, but without self-
organisation into a barrier urothelium (Varley et al., 2004a, 2004b,
2006, 2009). Thus, the outcomes of these two differentiation-inducing
protocols are not identical, yet both result in development of a
differentiated urothelial cell phenotype. We reasoned that comparison
of the two protocols to identify common changes in gene expression
over time would help limit method-dependent artefacts and hence
was a strategy that could help identify key regulatory genes involved
in determining urothelial differentiation.
To these ends, we performed a gene array series at different
time-points following differentiation induction using the two
differentiation-inducing protocols performed in parallel. Our aim
was to perform an unbiased analysis to identify common regula-
tory features and in the following, we describe the quality
assessment of the data, the overcoming of synchronisation issues
by performing a qualitative ranking approach, the identiﬁcation of
a set of signiﬁcant genes involved in transcriptional regulation and
the experimental validation of a previously unidentiﬁed regulator
of human urothelial cytodifferentiation.
Materials and methods
Troglitazone (TZ) was obtained from Sigma-Aldrich (Dorset,
UK) and the EGF receptor tyrosine kinase inhibitor PD153035 was
obtained from Merck Millipore (Darmstadt, Germany). The PPARγ-
speciﬁc antagonist, T0070907 was obtained from Cambridge
Bioscience (Cambridge, UK). Rabbit anti-ELF3 antibody (ab97310)
was obtained from Abcam, Cambridge, UK. Mouse anti-β-actin
(clone AC-15) was obtained from Sigma-Aldrich (Dorset, UK).
Tissue samples
Human urothelial tissue samples were sourced ethically with
informed written consent from patients and approval for use in
research from Leeds (East) and York Research Ethics Committees.
The surgical specimens were collected from patients with no
history of urothelial cancer and were processed for histology or
used to establish urothelial cell cultures. Samples taken for
(immuno)histology were ﬁxed for 16 h in 10% (v/v) formalin,
dehydrated and processed into parafﬁn wax.
Cell culture
Finite NHU cell lines were established as detailed elsewhere
(Southgate et al., 2002). For routine propagation, cultures were
maintained as monolayers in low calcium [0.09 mM] Keratinocyte
Serum Free Medium containing bovine pituitary extract and EGF
(Invitrogen) and further supplemented with cholera toxin
(KSFMc). Cultures were sub-cultured by trypsinisation at just-
conﬂuence and used for experiments between passages 3 to 5.
To induce differentiation, two previously described methods
were applied to just-conﬂuent NHU cell cultures. In the ﬁrst
(referred to as TZ/PD), cultures were treated with 1 mM TZ with
concurrent 1 mM PD153035 to block EGFR activation and induce
individual cell differentiation (Varley et al., 2004a). In the second
protocol (referred to as ABS/Ca2þ), cultures were pre-treated with
5% adult bovine serum (ABS, Harlan Sera-Lab) for 3 days before
subculture (time point T¼0 h) into KSFMc supplemented with 5%
ABS and 2 mM CaCl2, leading to generation of a differentiated,
tight barrier epithelium as described (Cross et al., 2005). Vehicle
control non-differentiated cultures were maintained in parallel in
KSFMc and used at the same time points (between 24 h to 144 h).
Cultures were lysed in situ with TRIzols to prepare RNA by the
manufacturer0s recommended protocol (Invitrogen). RNA samples
were treated with a DNA-free kit (Ambion) and quantiﬁed by UV
spectrophotometry.
Microarray experiments and preprocessing
Time series experiments were performed on two independent
donor NHU cell lines (Y579 and Y676) using the TZ/PD and ABS/
Ca2þ differentiation-inducing protocols described above. For each
arm of the experiment, parallel non-differentiated control cultures
were included and RNA was extracted at 6, 24, 72 and 144 h,
where t¼0 coincided with the treatment to induce differentiation
in the TZ/PD cultures. The nature of the differentiation process
meant that (as described above and (Cross et al., 2005)) the ABS/
Ca2þ arm had a serum pre-treatment stage, which affected
absolute synchronisation of the two arms of the experiment.
Following RNA extraction, induction of differentiation in the
experimental arms was veriﬁed by assessing the expression of
UPK2 transcript by quantitative real time PCR (not shown).
For the arrays, mRNA was converted to cDNA and then to
biotin-labelled cRNA before hybridising to HG-U133 Plus 2.0 arrays
(Affymetrix). The array chips were washed and scanned at 560 nm
using an Affymetrix GeneChip Scanner. Quality assessment of the
microarrays was performed with the arrayQualityMetrics package
(Kauffmann et al., 2009) and two samples were discarded due to
quality issues (one control sample: 72 h ABS/Ca2þ from cell line
M. Böck et al. / Developmental Biology 386 (2014) 321–330322
Y676; and one experimental sample: 6 h TZ/PD from cell line
Y676). The experiment thus yielded 30 arrays (2 cell lines (2
experimental and 2 control arms)4 time points)2 discarded
arrays).
All calculations were performed in R. The microarray data were
RMA normalised (Irizarry et al., 2003) using the Bioconductor
package affy (Gautier et al., 2004). To reduce the dimensionality of
the data and to ﬁlter out insigniﬁcant signals, an intensity ﬁlter
was applied, which retained probe sets for which at least 25 per
cent of all time points for the experimental time series had an
intensity above log 2ð100Þ. 25,461 probe sets remained after the
ﬁltering step, corresponding to about 13,500 genes. Since the time
series began at 6 h, the ﬁrst control time point was used as a zero
time point to account for changes of the expression level between
the starting point of the control cell lines and the experiments.
This left three time series with ﬁve time points and one with
four because of the discarded sample (the 6 h time point in the
TZ/PD Y676 experiment). The quality analysis and a principal
component analysis of the different samples are provided in the
Supplementary Materials (S1–S5). An interactive visualisation
of the results can be accessed from http://infosys.informatik.
uni-mainz.de/research/timeseries-visualisation/downloads.
Filtering and ranking
We developed an approach that focused on the expression
changes over time on a qualitative level to overcome the lack of
precise synchronisation of events. We searched only for the
maximum changing event per gene and experiment, and globally
compared changes over time from control to experiment, thus
avoiding the direct comparison of time points. We calculated for
each probe set time series a ΔX, the difference between the
maximum intensity of all time points xiAX (with i being the time
point one to ﬁve, including the ﬁrst control time point as zero time
point) to the minimum intensity of all time points
ΔX ¼maxðxi A XÞminðxj A XÞ ð1Þ
This difference ΔX describes the maximum change over time
per probe set for each time series. In a second step, we calculated
the difference of the scale120%Δscale100%Xexp for the experiment
and the scale120%Δscale100%Xctrl for the control time series. We
refer to this as the amplitude log fold change (ALFC):
ALFC ¼ scale120%Δscale100%Xexp scale120%Δscale100%Xctrl
ð2Þ
This value deﬁnes if a probe set changes signiﬁcantly over time
compared to its control, without having to compare the individual
time points. A positive ALFC means the change is larger for the
experiment and a negative value vice versa, indicating a silenced
gene. Probe sets were then ordered in decreasing order of their
ALFC value.
Validation experiments
In validation experiments, NHU cell cultures (independent cell
lines from arrays) were induced to differentiate by co-treatment
with 1 μM TZ and 1 μM PD153035 as described above and in
(Varley et al., 2004a). To further deﬁne the role of PPARγ, parallel
cultures were pretreated for 3 h with 5 μM T0070907 as a speciﬁc
PPARγ antagonist prior to induction of differentiation. Replicate
cultures were harvested at 6, 24, 48 and 72 h and used to extract
DNA-free RNA for analysis of transcript expression (see below).
Parallel cultures were lysed and processed for immunoblotting
and probed with rabbit anti-ELF3 antibody, which was also used to
assess ELF3 localisation in parafﬁn wax-embedded tissue sections
of human urothelium by immunoperoxidase histochemistry (see
below). Appropriate vehicle (DMSO), loading (β-actin for RT-PCR
and immunoblotting) and speciﬁcity (RT-negative and irrelevant
antibody) controls were included in all experiments.
Reverse-transcribed (RT) and real-time quantitative (RTq) PCR.
Cell cultures were solubilised in TRIzols and the RNA was
isolated by chloroform extraction and iso-propanol precipitation,
according to the manufacturer0s protocol (Life Technologies, Pais-
ley, UK). The RNA was treated with DNase I (DNA-free™ kit from
Ambion, Huntingdon, UK). cDNA was synthesised from 1 μg of
total RNA using the Superscript ﬁrst-strand synthesis system (Life
Technologies, Paisley, UK). RT-PCR was performed using Go Taqs
Hotstart Polymerase (Promega, Southampton, UK) with primer
sets designed to amplify speciﬁc human products (Table 1). RT
negative and no template (water) controls were always included.
For semi-quantitative analysis, template cDNA was mixed with
SYBRs Green PCR Master Mix (Applied Biosystems) and 300 nM of
each forward and reverse target gene primers (Table 1) and
analysed on an ABI StepOnePlus™ Real Time PCR System. The
thermal proﬁle was: 20 s hold at 95 1C, followed by 40 cycles of
denaturation at 95 1C (3 s) and elongation at 60 1C (30 s). Dis-
sociation curves were performed to conﬁrm the presence of a
single ampliﬁcation product and the absence of primer dimers for
each primer set. Assay efﬁciency, validated using the CT slope
method prior to use, conﬁrmed that both the test and endogenous
assays were of equivalent efﬁciency (within tolerance range).
SYBRs Green results were expressed as relative quantiﬁcation
(RQ) values (Applied Biosystems).
Immunohistochemistry
De-waxed 5 μm tissue sections were blocked for endogenous
peroxidase activity with 3% (v/v) hydrogen peroxide for 10 min.
Antigen retrieval was performed by microwave boiling of tissue
sections in a 10 mM citric acid buffer (pH 6.0) for 10 min, followed
by 10 min cooling on ice. Tissue sections were treated with an
Avidin/Biotin blocking kit (Vector labs, Peterborough, UK), before
Table 1
Primer sequences used for RTPCR and RTqPCR.
PCR product (gene name) Forward primer (50–30) Reverse primer (50–30)
ELF3 (RTPCR) GTTCATCCGGGACATCCTC GCTCAGCTTCTCGTAGGTC
ELF3 (RTqPCR) TCAACGAGGGCCTCATGAA TCGGAGCGCAGGAACTTG
GRHL3 (RTqPCR) TGGAATATGAGACGGACCTCACT CAGACACGTTCTCTGTCAGGAATT
FOXA1 (RTqPCR) CAAGAGTTGCTTGACCGAAAGTT TGTTCCCAGGGCCATCTGT
UPK3a (RTPCR) CGGAGGCATGATCGTCATC CAGCAAAACCCACAAGTAGAAAGA
UPK2 (RTqPCR) CAGTGCCTCACCTTCCAACA TGGTAAAATGGGAGGAAAGTCAA
CLDN7(RTqPCR) GCAGTGGCAGATGAGCTCCTAT CATCCACAGCCCCTTGTACA
β-actin (RTPCR) ATCATGTTTGAGACCTTCAA CATCTCTTGCTCGAAGTC
GAPDH (RTqPCR) CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG
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applying 10% goat serum for 5 min to prevent non-speciﬁc binding
of the secondary antibody. Rabbit anti-ELF3 antibody (2 μg/ml)
was applied, followed by biotinylated goat anti-rabbit secondary
antibody (1/800, Dako Cytomation Ltd, Ely, UK) – each for 15 min
at ambient temperature, with washing in between. Antibody
binding was detected using a tyramide-based signal ampliﬁcation
system (CSA system, Dako Cytomation Ltd, Ely, UK), as described in
the manufacturer0s protocol. Tissues were lightly counterstained in
Mayer0s haematoxylin, dehydrated through ethanol to xylene and
mounted in DPX (Sigma Aldrich).
Immunoblotting
Culture lysates were resolved on 4–12% gradient bis-Tris
acrylamide NuPAGEs gels (Life Technologies, Paisley, UK) and
electrotransferred onto 0.45-μm PVDF-FL membranes (Merck
Millipore, Darmstadt, Germany). Membranes were probed with
anti-ELF3 (1 μg/ml) and β-actin (1/250,000) antibodies for 16 h at
4 1C; bound antibody was detected with goat anti-rabbit Ig
conjugated to IRDyes 800 (50 ng/ml; Rockland Immunochem-
icals; supplied by Tebu-bio, Peterborough, UK) or anti-mouse
immunoglobulins conjugated to Alexa Fluors 680 (200 ng/ml;
Life Technologies), as appropriate. Immunolabelled protein bands
were visualised and relative quantiﬁcations generated using an
Odyssey infrared imaging system (LiCor, Cambridge, UK).
Knock-down of ELF3 by retroviral-mediated shRNA interference
For RNA interference experiments, siRNA oligos were designed
to target the ELF3 coding sequence before adding the hairpin loop,
restriction overhangs for directional cloning and an Mlu1 restric-
tion site (to verify cloned inserts) to generate the following ELF3









Oligonucleotides were annealed and cloned into the RNAi-
Ready pSIREN-RetroQ retroviral expression vector (Clontech) and
transfected into the PT67 packaging cell line using the man-
ufacturer0s protocols. An irrelevant shRNA was also prepared using
the control sequence provided by Clontech. Following antibiotic
selection, conditioned virion-containing medium was harvested
from conﬂuent PT67 cultures and ﬁltered through a 0.45 mm low
protein binding Tuffryns ﬁlter to remove cell debris. NHU cells
were transduced for 6 hr with 8 ml of conditioned medium
supplemented with 8 mg/ml Polybrene (Hexadimethrine Bromide,
Sigma), after which virus-containing medium was removed and
cultures replenished with KSFMc. Transduced NHU cell cultures
were selected with 1 mg/ml puromycin and screened for ELF3
protein expression by immunoblotting following induction of
differentiation.
Transepithelial electrical resistance (TER) studies
Differentiating urothelial cell cultures were established on
Snapwell™ membranes using the ABS/Ca2þ differentiation-
inducing protocol and with medium changed on alternative days.
TER readings were taken daily using a portable EVOM™ Epithelial
Volt-ohmmeter (World Precision Instruments), as described
(Rubenwolf and Southgate, 2011).
After stabilisation of the TER readings, cultures were scratched to
create a wound of 250 μm wide. Further TER measurements were
taken at regular intervals over a period of 61 h during wound closure.
Results
Candidate gene selection
The time series microarray data was pre-processed and ﬁltered as
described in the Methods section. The ﬁrst intensity ﬁltering left
25,461 probe sets (about 13,500 genes). The initial goal was to
prioritise and group genes with respect to their possible importance
in regulating the differentiation or proliferation process. The main
difﬁculty for the analysis of the time series data arose due to inherent
(a) variability between the two biological replicates (independent
human donor cell lines) studied and (b) differences in the pre-
treatment and hence precise timing of the two procedures (ABS/
Ca2þ and TZ/PD) used to induce differentiation. Together, these
confounded synchronisation of the experimental arms and impaired
direct comparison of control and experimental time points. To over-
come these issues, we developed an approach that focused on the
expression changes over time on a qualitative level, which we refer to
as the ALFC. Thus, instead of performing pairwise comparisons
between each time point of control and experiment, we looked for
the maximum expression burst in the time series for each gene and
compared the global expression change over time between the control
and experiment. By discretising the global differences between
experimental and control arms, we effectively circumvented any
problems related to shifts in timing between or within experiments.
The result was that we were able to avoid direct comparison of the
time points, whilst still considering the time information. An overview
of the resulting sets and their intersections is shown in Fig. 1.
The calculated ALFC was then used for further ﬁltering of the data
sets. We used a set of 25 pre-deﬁned marker genes selected as
implicated in urothelial differentiation or proliferation (Table 2) in
order to select the size of sets for further investigation. Fig. 2 shows
the stair-step plots with the number of markers included by applying
different thresholds for each of the four experimental arms (see
Table 3 for an overview of the included markers). Based on this
analysis, we selected the top 1000 ranked probe sets associated with
each experimental arm. We proceeded to analyse the different
intersections between the four selected top 1000 probe sets (see
Fig. 1A and B for an overview). By deﬁnition, the overlap between all
four experimental arms (two biological replicates and two
differentiation-inducing procedures) identiﬁed common (method-
independent) genes, whereas the overlap exclusive to either of the
two differentiation-inducing procedures (ABS/Ca2þ or TZ/PD)
revealed method-dependent factors.
Identiﬁcation of common regulatory genes implicated in urothelial
differentiation.
For the intersection of all four sets, the ALFC was normalised to
one for each experimental arm and the absolute sum of the ALFC
was calculated and used to prioritise the list of probe sets. The
overlap of all four experiments resulted in 189 probe sets and the
overlap of the ABS/Ca2þ arms resulted in 427 probe sets (see
Fig. 1C and D). The 20 top ranked genes on these lists are shown in
Table 4. We next used the dragon TcoF-DB (Schaefer et al., 2011) to
ﬁnd transcription factors (TFs) of interest within the two sets.
TcoF-DB currently consists of 1365 TFs which were manually
curated (Vaquerizas et al., 2009) or are contained in TRANSFAC,
where they have passed a manual curation step.
Four TFs (ELF3, BNC1, BCL6 and IRF1) were found in the overlap of
all four experiments and 13 TFs were associated with the ABS/Ca2þ
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overlap, of which nine TFs (GRHL1, GRHL3, FOXC1, ID2, SMAD3,
FOXN2, ETS1, MITF and FOXD1) remained after the TZ/PD arm was
ﬁltered out. It should be noted that the gene list for the ABS/Ca2þ
overlap does not necessarily exclude a gene from being also relevant
to the TZ/PD model: the list contains similar genes but the speciﬁc
ranking is based only on the ABS/Ca2þ arm.
ELF3 was the top ranked TF (overlap of all sets) with a larger ALFC
value than most other genes in all four differentiated datasets (see
Fig. 3). The 95% quantile of all probe sets (in the overlap of all sets) lay
at an ALFC value of 0.6, while the three probe sets for ELF3 represented
on the HG-U133 Plus 2.0 chip (210827_s_at, 229842_at, 201510_at)
reached values of 1.57, 2.06 and 1.72, respectively. A two-tailed p-value
test for all three probe sets was signiﬁcantly smaller than 0.05
(between 2.6e-10 and 5.3e-18). The main expression burst for ELF3
occurred early, between 0 h to 24 h, and increased in the case of the
TZ/PD arm until 72 h. As ELF3 has not been previously implicated in
human urothelial cytodifferentiation, we validated its expression in
human urothelium in situ and during differentiation of normal human
urothelial cells in vitro. In addition, we examined how the expression
of ELF3 was regulated in relationship to PPARγ activation.
Fig. 1. Overview of the probe set overlaps between the experiments. Figures A and B give an overview of how the top ranked probe sets were combined. The intersection was built
either on all four ﬁltered 1000 top ranked sets or the two ABS/Ca2þ experimental arms. The ALFC for each probe set was then normalised to one and the set sorted according to the
sum of absolute ALFC over all experiments. The intersection of the ABS/Ca2þ sets was ranked from the difference between the absolute sum of ALFC on the ABS/Ca2þ arm and the
absolute sum of the ALFC on the TZ/PD arm. Figures C and D display Venn diagrams which show the intersection and overlaps of the four differentiation series (TZ/PD and ABS/Ca2þ ,
on two independent donor cell lines Y579 and Y676). The overlaps were generated using the top 1000 probe set lists from each experiment; probe sets were used in order to keep the
gene lists as accurate as possible and to enable tracking back to the speciﬁc probe sets on the microarray which are contained in our ﬁnal lists. The Venn diagram in panel C shows the
number of genes present at the intersection of all four data sets. 142 up-/downregulated genes were found within the intersection. Within this subset, four TFs were found (ELF3, BCL6,
BNC1, IRF1). Figure D shows the same overlaps on the probe set level. The 189 probe sets in the intersection of all sets map to the 142 genes from Figure C. The overlap between the
ABS/Ca2þ experimental arms contains 472 probe sets with 13 identiﬁed as TFs (see Table 2 for details). From these 13 TFs, nine factors (GRHL1, GRHL3, FOXC1, ID2, SMAD3, FOXN2,
ETS1, MITF and FOXD1) were unique to the ABS/Ca2þ arm and not included in the TZ/PD lists.
Table 2
List of markers for probe set ﬁltering.
Expected expression versus control Marker genes
Expressed, but not expected to change KRT7, KRT19, GAPDH, ACTB, SMAD2,
Downregulated KRT5, KRT6A, KRT6B, SMURF2, SMAD7, MYBL2, BUB1, PLK1, CREB1
Upregulated early FOXA1, GATA3, IRF1, IRF2
Upregulated late KRT13, CLDN4, UPK2, UPK3A, UPK1A, UPK1B, UPK3B
This list gives an overview of the proliferation and differentiation-associated transcribed gene markers used to deﬁne the ﬁltering thresholds.
M. Böck et al. / Developmental Biology 386 (2014) 321–330 325
Validation of ELF3 expression by human urothelium.
By immunohistochemistry, ELF3 localised speciﬁcally to the
urothelium in sections of human ureter. The localisation pattern
was exclusively nuclear and the intensity of expression increased
from basal to the most differentiated superﬁcial cells (Fig. 4A).
In cultures of NHU cells induced to differentiate by activation of
PPARγ (through co-treatment with TZ and PD153035), ELF3
Fig. 2. Deﬁning the ALFC threshold. Stair-step plots for the four experiments showing the number of rediscovered markers in the data set for differently sized sets of top
ranked probe sets (up to 1500). The ranking was performed using the calculated ALFC and each bar represents the number of found markers for the particular amount of
chosen genes. A plateau around 1000 is reached in all four data sets and hence a threshold of choosing the top 1000 probe sets was applied for the second ﬁltering step. The
maximum amount of found markers is shown in brackets next to the experiment identiﬁer in the left corner of each chart.
Table 3
Overview of top ranked probe sets and their associated marker genes.
Experimental arm (cell
line)






TZ/PD (Y579) 1000 (707) 955 45 UPK1A, UPK1B, UPK2, UPK3A, IRF1, FOXA1, CLDN4, KRT5/6A/6B, SMAD7
TZ/PD (Y676) 1000 (695) 997 3 UPK1A, UPK1B, UPK2, UPK3A, UPK3B, ACTB, KRT5/6A/6B/13, IRF1, FOXA1, GATA3
ABS/Ca2þ (Y579) 1000 (731) 953 47 UPK1B, KRT5/6A/6B/13, IRF1, CLDN4
ABS/Ca2þ (Y676) 1000 (755) 996 4 UPK1A, UPK1B, UPK3A, UPK3B, IRF1, SMAD7, SMURF2, KRT5/6A/6B/13, CLDN4, FOXA1,
GATA3
This Table gives an overview of the four experiments with the top 1000 ranked probe sets (number of genes represented) according to ALFC and showing the associated
marker genes (from Table 2). Genes were assigned as positive (þ) or negative (–) depending on the ALFC value. A positive ALFC value indicates that over the time series, the
gene expression of the probe set for the experimental arm changed more than for the control arm.
Table 4
Overview of TFs and 20 top ranked genes within the overlaps of the experiments.
Overlap of all sets Overlap of ABS/Ca2þ experiments





RARRES1, LIMCH1, TRIM31, UBD, SPINK1, PDE10A, TMPRSS2, CP,
PIGR, C10orf116, HPGD, CX3CL1, GKN1, IGFBP3, ELF3, RHOU,
SYTL5, TFF1, MUC20, RARRES3
GRHL1, GRHL3, FOXC1, ID2,
BNC1, SMAD3, ELF3, BCL6,
FOXN2, ETS1, IRF1, MITF, FOXD1
MUC4, CLIC5, CXCL6, BCL2A1, DUOX2, SERPINB9,
SERPINA3, PIGR, MAP3K8, IDO1, IL1RL1n, ZG16B, IL8,
PDZRN3, RARRES3, MMP7, GABRPn, PPBPn, RARRES1
This table shows the lists of top ranked genes in the overlaps/intersections of all four experimental arms and for the two ABS/Ca2þ speciﬁc arms (see Fig. 2C and D). The
genes are ordered according to their ALFC. We observe for the TZ/PD model the largest gene expression burst between 24 h and 72 h. For the ABS/Ca2þ model, the burst
occured earlier, between 0 h and 6 h (but note that this protocol involves a priming pre-treatment). nThe majority of the genes are up-regulated, except the genes IL1RL1,
GAPRP and PPBP from the overlap of the ABS/Ca2þ arms.
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transcript expression was induced within 24 h and remained high
at 72 h. Inhibition of PPARγ activation by pretreatment of cells
with the speciﬁc PPARγ antagonist, T0070907, resulted in inhibi-
tion of ELF3 induction (Fig. 4B).
The ELF3 transcript results were conﬁrmed by immunoblotting
for ELF3 protein, which revealed upregulation of ELF3 protein at
24 h. Inhibition by pretreatment with T0070907 conﬁrmed that
this was a PPARγ-mediated process (Fig. 4C).
Immunoblotting revealed that retrovirally-transduced stable
expression of shRNA against the ELF3 protein coding sequence was
successful at inhibiting ELF3 protein expression following induction of
differentiation by PPARγ activation. Of the three shRNA sequences
tested, shRNA1 showed the most efﬁcient knockdown and was used
in subsequent experiments (Supplementary Materials S6). Following
induction of differentiation in response to PPARγ activation (TZ/PD
protocol), cells stably transduced with ELF3 shRNA1 showed reduced
induction of ELF3 transcript and of the terminal differentiation-
associated UPK3a gene, compared to the transduced control shRNA
cells (Fig. 5A). Quantitative analysis by real-time PCR of the ELF3
knock-down cultures showed reduced differentiation-induced
expression of CLDN7 and of the transcription factors FOXA1 and
GRHL3 (Fig. 5B).
To assess the consequence of ELF3 knockdown on differentiated
urothelial barrier function, TER was used to monitor barrier
development post-induction of differentiation using the ABS/
Ca2þ protocol. A measurable barrier ﬁrst became apparent at four
days post-induction of differentiation in both the control and ELF3
knockdown cells, but the ultimate TER attained was signiﬁcantly
reduced in the latter (control versus ELF3k/d: 34207443 versus
20617176 Ω cm2; po0.001 7sd; n¼6; Fig. 5C). Following
scratch wounding of the cultures, initiation of barrier repair was
less efﬁcient and the ﬁnal barrier attained was reduced in the ELF3
knockdown cells compared to the shRNA control transduced cells
(Fig. 5D).
Discussion
Much has been learned about transcriptional regulation during
tissue development from null expression studies in transgenic
mice, but translation to human systems is more challenging. Here
we demonstrate how bioinformatics analysis of a normal human
differentiating cell culture time series can identify key transcrip-
tional regulators involved in human tissue-speciﬁc determination
and differentiation, and provide insight into the relationships and
hierarchies of the transcriptional networks.
We have described a qualitative approach for the analysis of
asynchronous time series data and applied it to four gene expres-
sion time series representing two differentiation-inducing proto-
cols in bladder and ureter derived ﬁnite normal human urothelial
Fig. 3. ALFC values for ELF3 and GRHL3. ALFC values for the probe sets of two genes of interest, ELF3 and GRHL3. The mean ALFC of all probe sets is shown by the green bars.
For the two genes the ALFC is signiﬁcantly larger than for the average probe set.
Fig. 4. Experimental validation of ELF3. ELF3 immunolocalisation in human urothe-
lium on a section of normal ureter (A). Note nuclear localisation and increased intensity
in the most highly differentiated superﬁcial cells (Scale bar¼50 μM). Expression of
ELF3 transcript (B) and protein (C) was examined in NHU cells induced to differentiate
in response to the TZ/PD protocol. The antagonist T0070907 was used to conﬁrm
speciﬁc involvement of PPARγ. Cells were pre-treated with 5 μM T0070907 (or vehicle
control) for 3 h prior to addition of 1 μM TZ and 1 μM PD153035. RNA extractions and
whole-cell protein lysates were collected for analysis at 6, 24, 48 and 72 h post-
treatment. At each time point a DMSO vehicle control was included. For transcript
analysis (B), ELF3 gene expression was analysed by RT-PCR and β-actin was included as
a normalisation control. Whole cell lysates were processed for western blotting (C) and
labelled with antibodies against ELF3 or β-actin as loading control.
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cell lines. Unlike other methods for analysing short time series
(Conesa et al., 2006; Zoppoli et al., 2010), our method is directly
applicable to analysing non-synchronous short time series and
overcomes issues of missing time points or replicates. The result of
our analysis is a ranked list that offers an intuitive pipeline for
successive iterations between data analysis and biological evalua-
tion to attain a manageable set of candidate genes. The same
approach can be used to look for speciﬁc differences between
different experimental arms to identify genes upregulated by
one protocol only. For example, such analyses could provide
insight as to why the ABS/Ca2þ protocol generates a differentiated
multi-layered and functional barrier urothelium, compared to the
generation of differentiated but non-organised monolayer cell
cultures that result from the TZ/PD protocol.
In this report, we concentrated on identifying common
(method-independent) genes involved in regulating the develop-
ment of a differentiated phenotype from normal human urothelial
cells. The culture system is such that it maintains NHU cells in a
proliferative squamous basal phenotype, characterised by CK14þ/
CK13expression (Southgate et al., 1994) and we have shown that
PPARγ activation (Varley et al., 2004a, 2004b, 2006) or subculture
in serum (Cross et al., 2005) can switch cells into a differentiating
CK14/CK13þ transitional epithelial programme. Our analysis has
identiﬁed the epithelium-speciﬁc Ets domain transcription factor
ELF3 as a differentiation-associated gene whose expression is
regulated downstream of PPARγ. In mice, ELF3 has been shown
to be induced in the urothelium following infection with uro-
pathogenic Escherichia coli (UPEC) (Mysorekar et al., 2002). Infec-
tion of the bladder epithelium of mice with UPEC triggers a
response in which bacterial-laden superﬁcial cells are exfoliated
and the urothelium is reconstituted through differentiation of
underlying basal and intermediate cells (Mysorekar et al., 2002).
One of the early transcriptional responses to attachment of the
UPECs is thought to be upregulation of the transcription factor
ELF3, which has also been implicated in keratinocyte terminal
differentiation (Andreoli et al., 1997; Oettgen et al., 1997). Mysor-
ekar and colleagues hypothesised that ELF3 has a dual role in
regulating urothelial differentiation and mediating host defence
through transactivation of iNOS (Mysorekar et al., 2002). Targeted
disruption of ELF3 in the mouse resulted in 30% lethality, with the
remaining offspring reported as showing disrupted morphological
and cellular differentiation of the small intestinal epithelium (Ng
et al., 2002). ELF3-deﬁcient enterocytes expressed markedly
reduced levels of the transforming growth factor type II receptor
(TGFβRII) and could be genetically rescued by introduction of a
human TGFβRII transgene, demonstrating that Elf3 is the critical
upstream regulator of TGFβRII in the mouse small intestinal
epithelium (Flentjar et al., 2007). Transcriptional reprogramming
of the TGFβR pathway, including downregulation of TGFβRII, has
been documented in NHU cytodifferentiation (Fleming et al.,
2012). However, TGFβR signalling was not associated in urothelial
differentiation itself and instead was implicated in priming an
autocrine tissue repair programme (Fleming et al., 2012).
A GRHL3-null mouse embryo model was used to demonstrate
that the transcriptional regulator GRHL3 is required for formation
of normal superﬁcial cells and terminal differentiation of bladder
urothelium (Yu et al., 2009). The gene and protein expression of
the uroplakins was signiﬁcantly downregulated in bladders of
GRHL3-null mice and a functional GRHL3 binding site was identi-
ﬁed on the UPK2 gene promoter. More recently it has been
proposed that the transcriptional regulator KLF5 is required for
urothelial maturation and differentiation (Bell et al., 2011). Thus, in
mice with KLF5 deﬁcient bladder epithelium, the urothelium fails
to stratify and there was reduced expression of terminal
Fig. 5. Analysis of ELF3 knock-down on NHU cytodifferentiation and barrier repair. Expression of urothelial differentiation-associated genes was examined in ELF3 versus
control shRNA transduced cells. (A) Scrambled shRNA control (ctrl) and ELF3 knockdown (k/d) cells cultures were exposed to vehicle only (0.1% DMSO) or differentiated by
co-treatment with TZ and PD153035 (TZ/PD) and the expression of ELF3 and late differentiation-associated UPK3a was analysed by RT-PCR at 48 h and 72 h post-treatment.
(B) The expression of ELF3, GRHL3, FOXA1 and claudin 7 was analysed by RTqPCR in cells transduced with control versus ELF3 shRNA at 48 h post differentiation with TZ/PD.
In A and B, the reaction controls included an RT-negative for each RNA sample, a no-template (H2O) control, a β-actin normalisation control and a genomic DNA positive
control. (C) Barrier function in ELF3 versus control shRNA transduced cultures was followed over an 8 day period following differentiation in ABS/Ca2þ by measurement of
the TER. D) The same cultures were then wounded and the restoration of barrier function was observed over the subsequent 61 h. Statistical analysis was calculated by
ANOVA with Bonferroni Multiple Comparisons post-test (***Po0.001, **Po0.01).
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differentiation markers, including uroplakins and claudins. Eleven
transcription factors were downregulated in KLF5-deﬁcient blad-
der urothelium including PPARγ, ELF3, FOXA1 and GRHL3. The
murine GRHL3 gene has been shown to be a downstream target of
KLF5 and it has therefore been proposed that PPARγ and GRHL3
participate in a KLF5-dependent transcriptional network regulat-
ing urothelial differentiation (Bell et al., 2011).
We have previously shown a speciﬁc role for PPARγ in the
induction of differentiation in normal human urothelial cell
cultures, which depends both on the suppression of EGFR activity
and availability of activating ligand (Varley et al., 2004a). PPARγ
activation leads to de novo expression of intermediary transcrip-
tion factors including FOXA1 and IRF1 that act directly as tran-
scription factors for inducing the de novo expression of uroplakins
and other genes associated with urothelial differentiation (Varley
et al., 2009). ELF3 lies downstream of PPARγ: it has predicted PPAR
response elements in the promoter and is induced speciﬁcally by
PPARγ activation. We have now demonstrated that ELF3 inﬂuences
urothelial differentiation, as the induction of UPK3a expression
and the ultimate acquisition of barrier function were both inhib-
ited by ELF3 knockdown. The effect on ELF3 on UPK3a transcrip-
tion must be indirect as no Ets binding sites are predicted in the
UPK gene promoters (not shown), although as shown by knock-
down, ELF3 does inﬂuence expression of other implicated tran-
scriptional regulators including FOXA1 and GRHL3.
In conclusion, we propose a hierarchy in the speciﬁcation of
human urothelium that has ELF3 downstream of PPARγ, but
upstream of GRHL3 and FOXA1. We suggest that our strategy of
studying the temporal development of a differentiated phenotype
in vitro can help unravel the hierarchical relationships between
candidate transcription factors and their individual roles in the
differentiation programme and we have provided a new approach
for extracting this information from gene array studies.
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